Table 1 Overview of patients’ characteristics.
| Â | Frequency | Percentage |
|---|---|---|
Sex | ||
 Male | 72 | 79% |
 Female | 19 | 21% |
Median age 65 years [range 40–83] | – | – |
Histological subtype | ||
 Clear cell RCC (ccRCC) | 72 | 79% |
 Non-clear cell RCC (nccRCC) | 12 | 13% |
 Papillary RCC (pRCC) | 9 | 75% |
 Chromophobe RCC (chRCC) | 1 | 8% |
 Collecting duct carcinoma (CDC) | 1 | 8% |
 Tubulocystic RCC (tRCC) | 1 | 8% |
 Undefined subtype | 7 | 8% |
Prior systemic treatment (n = number of lines) | ||
 No | 71 | 78% |
 Yes (1) | 10 | 11% |
 Yes (≥ 2) | 10 | 11% |
Treatment after biopsy (N = 84) | ||
 Tyrosine kinase inhibitors (TKIs) | 61 | 73% |
 Pazopanib | 36 | 59% |
 Sunitinib | 23 | 38% |
 Cabozantinib | 1 | 1.6% |
 Lenvatinib | 1 | 1.6% |
 Immune checkpoint inhibitors (ICIs) | 19 | 23% |
 Nivolumab monotherapy | 13 | 68% |
 Nivolumab + ipilimumab | 6 | 32% |
 Combination treatment | 4 | 5% |
 Avelumab + axitinib | 4 | 100% |
